Potent	O
and	O
Targeted	O
Activation	O
of	O
Latent	O
HIV	O
-	O
1	O
Using	O
the	O
CRISPR	O
/	O
dCas9	O
Activator	O
Complex	O
.	O


HIV	O
-	O
1	O
provirus	O
integration	O
results	O
in	O
a	O
persistent	O
latently	O
infected	O
reservoir	O
that	O
is	O
recalcitrant	O
to	O
combined	O
antiretroviral	O
therapy	O
(	O
cART	O
)	O
with	O
lifelong	O
treatment	O
being	O
the	O
only	O
option	O
.	O


The	O
"	O
shock	O
and	O
kill	O
"	O
strategy	O
aims	O
to	O
eradicate	O
latent	O
HIV	O
by	O
reactivating	O
proviral	O
gene	O
expression	O
in	O
the	O
context	O
of	O
cART	O
treatment	O
.	O


Gene	O
-	O
specific	O
transcriptional	O
activation	O
can	O
be	O
achieved	O
using	O
the	O
RNA	O
-	O
guided	O
CRISPR	O
-	O
Cas9	O
system	O
comprising	O
single	O
guide	O
RNAs	O
(	O
sgRNAs	O
)	O
with	O
a	O
nuclease	O
-	O
deficient	O
Cas9	O
mutant	O
(	O
dCas9	O
)	O
fused	O
to	O
the	O
VP64	O
transactivation	O
domain	O
(	O
dCas9	O
-	O
VP64	O
)	O
.	O


We	O
engineered	O
this	O
system	O
to	O
target	O
23	O
sites	O
within	O
the	O
long	O
terminal	O
repeat	O
promoter	O
of	O
HIV	O
-	O
1	O
and	O
identified	O
a	O
"	O
hotspot	O
"	O
for	O
activation	O
within	O
the	O
viral	O
enhancer	O
sequence	O
.	O


Activating	O
sgRNAs	O
transcriptionally	O
modulated	O
the	O
latent	O
proviral	O
genome	O
across	O
multiple	O
different	O
in	O
vitro	O
latency	O
cell	O
models	O
including	O
T	O
cells	O
comprising	O
a	O
clonally	O
integrated	O
mCherry	O
-	O
IRES	O
-	O
Tat	O
(	O
LChIT	O
)	O
latency	O
system	O
.	O


We	O
detected	O
consistent	O
and	O
effective	O
activation	O
of	O
latent	O
virus	O
mediated	O
by	O
activator	O
sgRNAs	O
,	O
whereas	O
latency	O
reversal	O
agents	O
produced	O
variable	O
activation	O
responses	O
.	O


Transcriptomic	O
analysis	O
revealed	O
dCas9	O
-	O
VP64	O
/	O
sgRNAs	O
to	O
be	O
highly	O
specific	O
,	O
while	O
the	O
well	O
-	O
characterized	O
chemical	O
activator	O
TNFalpha	O
induced	O
widespread	O
gene	O
dysregulation	O
.	O


CRISPR	O
-	O
mediated	O
gene	O
activation	O
represents	O
a	O
novel	O
system	O
which	O
provides	O
enhanced	O
efficiency	O
and	O
specificity	O
in	O
a	O
targeted	O
latency	O
reactivation	O
strategy	O
and	O
represents	O
a	O
promising	O
approach	O
to	O
a	O
"	O
functional	O
cure	O
"	O
of	O
HIV	S-DISEASE
/	O
AIDS	S-DISEASE
.	O
